Literature DB >> 27894705

Surgical treatment of early-stage ovarian cancer.

Jason B Trimbos1.   

Abstract

The treatment of early-stage (stages I-IIA) ovarian carcinoma is predominantly surgical, and the surgical staging is the most relevant step in the treatment of this disease. The significance of surgical staging is twofold. First, proper staging distinguishes between 'real' early-stage ovarian carcinoma and 'perhaps' early-stage disease. The latter carries an appreciable likelihood of unappreciated residual disease in 16-42% of cases. Second, there is solid proof that proper surgical staging is an independent prognostic factor for improved disease-free and overall survival in early-stage ovarian carcinoma. In this chapter, the relevance of various staging steps is discussed and surgical guidelines are given. The indication for adjuvant chemotherapy after surgery is closely related to the adequacy of surgical staging. Adjuvant chemotherapy only works in patients in whom surgical staging was inadequate and who, thus, remain with a certain risk of unnoticed residual intraperitoneal or retroperitoneal tumour spread. Moreover, there is no indication that adjuvant chemotherapy is of any value after an adequate, comprehensive staging procedure. Controversies and misunderstandings on this important issue are discussed.
Copyright © 2016. Published by Elsevier Ltd.

Entities:  

Keywords:  adjuvant chemotherapy; early ovarian cancer; ovarian cancer treatment; staging steps; surgery; surgical staging

Mesh:

Substances:

Year:  2016        PMID: 27894705     DOI: 10.1016/j.bpobgyn.2016.10.001

Source DB:  PubMed          Journal:  Best Pract Res Clin Obstet Gynaecol        ISSN: 1521-6934            Impact factor:   5.237


  9 in total

Review 1.  O-RADS MRI Risk Stratification System: Guide for Assessing Adnexal Lesions from the ACR O-RADS Committee.

Authors:  Elizabeth A Sadowski; Isabelle Thomassin-Naggara; Andrea Rockall; Katherine E Maturen; Rosemarie Forstner; Priyanka Jha; Stephanie Nougaret; Evan S Siegelman; Caroline Reinhold
Journal:  Radiology       Date:  2022-01-18       Impact factor: 11.105

Review 2.  Ovary: MRI characterisation and O-RADS MRI.

Authors:  Elizabeth A Sadowski; Katherine E Maturen; Andrea Rockall; Caroline Reinhold; Helen Addley; Priyanka Jha; Nishat Bharwani; Isabelle Thomassin-Naggara
Journal:  Br J Radiol       Date:  2021-04-30       Impact factor: 3.629

Review 3.  Spotlight on olaparib in the treatment of BRCA-mutated ovarian cancer: design, development and place in therapy.

Authors:  Domenica Lorusso; Elisa Tripodi; Giuseppa Maltese; Stefano Lepori; Ilaria Sabatucci; Giorgio Bogani; Francesco Raspagliesi
Journal:  Drug Des Devel Ther       Date:  2018-05-29       Impact factor: 4.162

4.  MDR1 Gene Polymorphisms and Its Association With Expression as a Clinical Relevance in Terms of Response to Chemotherapy and Prognosis in Ovarian Cancer.

Authors:  Absarul Haque; Khalid Hussain Wali Sait; Qamre Alam; Mohammad Zubair Alam; Nisreen Anfinan; Abdul Wahab Noor Wali; Mahmood Rasool
Journal:  Front Genet       Date:  2020-05-26       Impact factor: 4.599

5.  Early-Stage Ovarian Malignancy Score versus Risk of Malignancy Indices: Accuracy and Clinical Utility for Preoperative Diagnosis of Women with Adnexal Masses.

Authors:  Phichayut Phinyo; Jayanton Patumanond; Panprapha Saenrungmuaeng; Watcharin Chirdchim; Tanyong Pipanmekaporn; Apichat Tantraworasin; Theera Tongsong; Charuwan Tantipalakorn
Journal:  Medicina (Kaunas)       Date:  2020-12-16       Impact factor: 2.430

6.  Incomplete surgical staging in clinical early-stage ovarian cancer: guidelines versus daily practice.

Authors:  P Laven; J J Beltman; J E Bense; M A van der Aa; T Van Gorp; M C Vos; D Boll; Hgj Arts; N Reesink; J B Trimbos; Rfpm Kruitwagen
Journal:  Surg Open Sci       Date:  2021-10-14

7.  Protein tyrosine phosphatase receptor type Z1 inhibits the cisplatin resistance of ovarian cancer by regulating PI3K/AKT/mTOR signal pathway.

Authors:  Peng Wang; Yuanjing Hu; Pengpeng Qu; Ying Zhao; Jing Liu; Jianguo Zhao; Beihua Kong
Journal:  Bioengineered       Date:  2022-01       Impact factor: 3.269

Review 8.  Natural Compounds with Potential to Modulate Cancer Therapies and Self-Reactive Immune Cells.

Authors:  Rhiane Moody; Kirsty Wilson; Anthony Jaworowski; Magdalena Plebanski
Journal:  Cancers (Basel)       Date:  2020-03-13       Impact factor: 6.639

9.  Interaction Analysis of MRP1 with Anticancer Drugs Used in Ovarian Cancer: In Silico Approach.

Authors:  Absarul Haque; Ghazanfar Ali Baig; Abdulelah Saleh Alshawli; Khalid Hussain Wali Sait; Bilal Bin Hafeez; Manish Kumar Tripathi; Badrah Saeed Alghamdi; Hani S H Mohammed Ali; Mahmood Rasool
Journal:  Life (Basel)       Date:  2022-03-07
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.